

DOCKET NO.: Y0087.70010US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

A. Schepartz Shrader, et al.

Serial No.:

09/840,085

Confirmation No.:

2186

Filed:

April 24, 2001

For: ·

DNA & PROTEIN BINDING MINIATURE PROTEINS

Examiner:

M. P. Allen

Art Unit:

1647

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 24th day of May , 2007.

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF DISCLOSURE UNDER 37 C.F.R. §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicants request consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed more than three months after the filing date of this application and after the mailing date of the first Office action, but before the mailing date of any final action under 37 C.F.R. §1.113, a Notice of Allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in this application.

The Applicants hereby state, as specified in 37 C.F.R. §1.97(e), that each item of information contained in this Information Disclosure Statement was first cited in any

Serial No.: 09/840,085 -2 - Art Unit: 1647

Conf. No.: 2186

communication from a foreign Patent Office in a counterpart for this application not more than three months prior to the filing of this Statement. No fee is required.

PART II: Information Cited

The Applicants hereby make of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

- 1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
- 2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
- 3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicants make no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicants make no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Serial No.: 09/840,085 - 3 - Art Unit: 1647

Conf. No.: 2186

Notwithstanding any statements by the Applicants, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,

By:

Patricia Granahan (

Reg. No. 32,227

Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

Boston, Massachusetts 02210-2206

Telephone: (617) 646-8000

Date: May 24, 2007

MAY 2	. se							
130	l P (modifie	1 DT()/SD/()8\	APPLICATION NO.: 09/840,085			ATTY. DOCKET NO.: Y0087.70010US00		
		PTO/SB/08)	FILING DATE:		April 24, 2001	CONFIRMATION NO.: 2186		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT: S		Schepartz Shrader et al.		
Sheet 1 of 1				GROUP ART UNIT: 1647		1647	EXAMINER: M. P. Allen	
				U.S. 1	PATENT DO	CUMENTS		
Examiner's Initials #	Cite	U.S. Patent Document			Name of Patentee or Applicar		t of Cited Date of Publication or Issue	
	No.	I		Kind Code	Document			of Cited Document MM-DD-YYYY
	1			1				

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited	Date of Publication of	Translation
		Office/ Country	Number	Kind Code	Document Document	Cited Document MM-DD-YYYY	(Y/N)

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		GUNNERSON, E. ET AL., "Affinity maturation of a Taq DNA polymerase specific antibody by helix shuffling," <i>Protein Engineering</i> , (October 1999), p.873-878; vol. 12, no. 10, Oxford University Press, Surrey, GB	

EXAMINER:	DATE CONSIDERED:

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

[#] EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

^{*}a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).